|
Stony Brook tapped for CardioCell recruitment
April 2015
SHARING OPTIONS:
STONY BROOK, N.Y.—CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary, has announced that patient recruitment for its Phase 2a clinical trial for heart failure has been
expanded to Stony Brook University’s Heart Institute. The study is seeking to
determine if the stem cell properties of CardioCell’s ischemia-tolerant mesenchymal stem cells (itMSCs) can cause a patient’s own cardiomyocytes
to improve their ability to contract, which could improve or restore heart function.
“The Heart Institute of
Stony Brook University Medical Center is ideally suited for CardioCell’s chronic HF study,” says Dr. Sergey Sikora, CardioCell’s president
and CEO. “The hospital delivers superior cardiovascular care to all of Long Island and surrounding areas, and its state-of the-art labs are staffed by
experts at handling live cells like the itMSCs used in this study’s protocols.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|